THEMISMEDNSEThemis Medicare Limited· PharmaceuticalsHighNeutral
Announced Fri, 1 Aug · 19:13 IST

Themis Medicare Limited has informed the Exchange that Record date for the purpose of Dividend is 05-Sep-2025.

Revenue DeclinePat NegativeExceptional ItemEbitda Margin CompressionResults View source PDF

THEMISMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Themis Medicare's board approved its Q1 FY26 (quarter ended June 30, 2025) unaudited financial results, reporting standalone revenue of ₹9,757.77 lakhs, down about 20.7% from ₹12,299.38 lakhs in the same quarter last year. The company swung from a profit of ₹1,871.47 lakhs in Q1 FY25 to a loss of ₹1,537.37 lakhs in Q1 FY26, with loss per share of ₹1.67 versus earnings of ₹2.03 a year ago. The results include an exceptional charge of ₹129.39 lakhs linked to the strike-off of its UK wholly-owned subsidiary, Carpo Medicals Limited. The board also withdrew the previously announced merger scheme with Gujarat Themis Biosyn Limited, appointed Ms. Neha Thakore as an additional non-executive independent director and Mr. Viraj Save as Executive President – Sales & Marketing, and fixed September 5, 2025 as the record date for the final dividend for FY25.

Likely market impact

Negative near-term sentiment is likely given the sharp revenue decline and swing to a quarterly loss, though the company has confirmed a dividend and signaled a renewed focus on its core domestic formulations business. Shareholders should watch for whether the Q1 weakness stabilises in the coming quarters.